ALLK - Allakos Inc.
| Previous Close | 117.36 |
| Open | 114.01 |
| Bid | 117.23 x 800 |
| Ask | 117.72 x 800 |
| Day's Range | 114.01 - 120.32 |
| 52 Week Range | 30.32 - 139.99 |
| Volume | 891,181 |
| Avg. Volume | 406,026 |
| Market Cap | 5.846B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
- MarketWatch
Allakos stock jumps in afternoon trading
Shares of Allakos Inc. rallied 37% in afternoon trading, to a record high. Sources told Bloomberg that the Redwood, Calif.-based biopharmaceutical company, which went public in August, is considering a sale. Allakos is in the early stages of developing treatments for eosinophilic gastritis and allergic conjunctivitis, among others. The rally has added roughly $1.7 billion to the company's market capitalization, to boost the market cap to about $6.4 billion. The company has not immediately responded to a request for comment. Allakos stock is up 146% year-to-date. The S&P 500 has gained 24%.
- Insider Monkey
Allakos Inc. (ALLK): These Hedge Funds Regret Cashing Out Too Early
Is Allakos Inc. (NASDAQ:ALLK) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
- American City Business Journals
These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
- Motley Fool
Why Allakos Stock Skyrocketed 154% in August
Investors were enthused about this biotech's positive phase 2 results for its lead investigational therapy, AK002.
- Zacks
Will Allakos Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Allakos.
- Zacks
Top Ranked Momentum Stocks to Buy for August 9th
Top Ranked Momentum Stocks to Buy for August 9th
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For August 7, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Walt Disney Co (NYSE: DIS ) shares were down ...
- Market Realist
Why Is Allakos Soaring Today?
Today, Allakos (ALLK) announced favorable results from its Phase 2 trial evaluating investigational therapy AK002.
- Schaeffer's Investment Research
Pharma Stock Set to Double Today
The stock is at the top of the Nasdaq today
- TheStreet.com
Allakos Stock Doubles on Positive Stomach Disease Drug Study Data
Analyst at William Blair says Allakos is a leader in research for a treatment for a rare stomach disease.
- Simply Wall St.
Imagine Owning Allakos (NASDAQ:ALLK) And Wondering If The 17% Share Price Slide Is Justified
Investors can approximate the average market return by buying an index fund. While individual stocks can be big...
- Insider Monkey
Is Allakos Inc. (ALLK) A Good Stock To Buy?
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
- Zacks
Allakos Enters Oversold Territory
Allakos Inc. (ALLK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Zacks
5 Best-Performing IPOs of 2018
Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.
- Zacks
Allakos (ALLK) Catches Eye: Stock Jumps 6.5%
Allakos (ALLK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
